Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Clinical trial NCT06361758 · WITHDRAWN

Trial details

NCT number: NCT06361758
Sponsor: Shanghai Zhongshan Hospital
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2024-05-31
Primary completion: 2026-05-31
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.